It's frustrating to find a company/stock combination where you really like the basic business and where the stock has underperformed, but where the shares also still look too expensive. Such seems to be the case with Catalent (NYSE:CTLT). I like the pharmaceutical contract manufacturing business, and I like Catalent's strong leadership across multiple formulation technologies and its efforts to grow the biologicals business, but it is hard to model a credible outlook that leads to the conclusion that the shares are too cheap today.
Read more here:
Catalent's Price Is A Little Hard To Swallow